MS drug pricing not based on R&D costs, pharma execs say

(By Maia Anderson for Becker’s Hospital Review)

Though drugmakers often claim their prices are based on the cost of a drug’s research and development, a report published Nov. 25 in Neurology suggests corporate growth objectives and competition are what actually drive costs for multiple sclerosis drugs, according to STAT.   Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.